Aktuellt
SENASTE
Moberg Pharma's Q4 2019/20 report included a few news items. The company's focus remains on its strategy for MOB-015. The results of its ph III trial may be enough for product registration in Europe, but an additional study will be needed for the US market. This underlying uncertainty clouds the outlook for Moberg Pharma, in our view. We make no meaningful revisions to our estimates following the report.
LÄS MER
